Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.
The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...
The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.
Hosted on MSN1d
Innate Pharma doses first patient in Nectin-4 ADC trialThe Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...
The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
Bristow's report suggests that the current share price does not account for the potential success of subsequent programs, including those for head and neck squamous cell carcinoma (HNSCC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback